US2014135480A1PendingUtilityA1

Compositions and Methods for the Therapy and Diagnosis of Influenza

62
Assignee: THERACLONE SCIENCES INCPriority: Nov 12, 2007Filed: Jun 10, 2013Published: May 15, 2014
Est. expiryNov 12, 2027(~1.3 yrs left)· nominal 20-yr term from priority
Inventors:Andres G. Grandea, IiiGordon KingThomas C. CoxOle OlsenJennifer MitchamMatthew Moyle
C07K 2317/32C07K 2317/21A61P 43/00A61K 2039/505C12N 2760/16122C07K 14/005A61P 31/16G01N 33/56983C07K 2317/34A61P 37/02C07K 16/108C07K 16/1018
62
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides novel human anti-influenza antibodies and related compositions and methods. These antibodies are used in the diagnosis and treatment of influenza infection.

Claims

exact text as granted — not AI-modified
1 - 41 . (canceled) 
     
     
         42 . A recombinant anti-matrix 2 ectodomain (M2e) antibody comprising a variable heavy chain region encoded by a nucleic acid sequence comprising the nucleic acid sequence of SEQ ID NO: 43 and a variable light chain region encoded by a nucleic acid sequence comprising the nucleic acid sequence of SEQ ID NO: 45. 
     
     
         43 . The antibody of  claim 42 , wherein the nucleic acid sequence comprising the nucleic acid sequence of SEQ ID NO: 43 is a cDNA and the nucleic acid sequence comprising the nucleic acid sequence of SEQ ID NO: 45 is a cDNA. 
     
     
         44 . The antibody of  claim 42 , wherein the nucleic acid sequence of SEQ ID NO: 43 is a cDNA and the nucleic acid sequence of SEQ ID NO: 45 is a cDNA. 
     
     
         45 . A vector comprising a nucleic acid sequence comprising the nucleic acid sequence of SEQ ID NO: 43 and a nucleic acid sequence comprising the nucleic acid sequence of SEQ ID NO: 45. 
     
     
         46 . The vector of  claim 45 , wherein the nucleic acid sequence comprising the nucleic acid sequence of SEQ ID NO: 43 is a cDNA or the nucleic acid sequence comprising the nucleic acid sequence of SEQ ID NO: 45 is a cDNA. 
     
     
         47 . The vector of  claim 45 , wherein the vector is vector suitable for propagation or replication of the nucleic acid. 
     
     
         48 . The vector of  claim 45 , wherein the vector is vector suitable for expressing the nucleic acid. 
     
     
         49 . The vector of  claim 47  or  48 , wherein the vector comprises a virus, a plasmid, or a cosmid. 
     
     
         50 . The vector of  claim 49 , wherein the virus is a recombinant virus. 
     
     
         51 . The vector of  claim 50 , wherein the virus comprises a promoter obtained from a mammalian genome. 
     
     
         52 . The vector of  claim 51 , wherein the mammalian genome is a human genome. 
     
     
         53 . The vector of  claim 50 , wherein the virus comprises a promoter obtained from a genome of a virus or a retrovirus. 
     
     
         54 . The vector of  claim 53 , wherein the virus or retrovirus is a polyoma virus, fowlpox virus, adenovirus, bovine papilloma virus, avian sarcoma virus, cytomegalovirus (CMV), hepatitis-B virus, or a Simian Virus 40 (SV40). 
     
     
         55 . A recombinant anti-matrix 2 ectodomain (M2e) antibody comprising a nucleic acid sequence encoding a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 44 and a nucleic acid sequence encoding a variable light chain region comprising the amino acid sequence of SEQ ID NO: 46. 
     
     
         56 . The antibody of  claim 55 , wherein the nucleic acid sequence encoding a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 44 is a cDNA and the nucleic acid sequence encoding a variable light chain region comprising the amino acid sequence of SEQ ID NO: 46 is a cDNA. 
     
     
         57 . A vector comprising a nucleic acid sequence encoding a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 44 and a nucleic acid sequence encoding a variable light chain region comprising the amino acid sequence of SEQ ID NO: 46. 
     
     
         58 . The vector of  claim 57 , wherein the nucleic acid sequence encoding a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 44 is a cDNA or the nucleic acid sequence encoding a variable light chain region comprising the amino acid sequence of SEQ ID NO: 46 is a cDNA. 
     
     
         59 . The vector of  claim 57 , wherein the vector is vector suitable for propagation or replication of the nucleic acid. 
     
     
         60 . The vector of  claim 57 , wherein the vector is vector suitable for expressing the nucleic acid. 
     
     
         61 . The vector of  claim 59  or  60 , wherein the vector comprises a virus, a plasmid, or a cosmid. 
     
     
         62 . The vector of  claim 61 , wherein the virus is a recombinant virus. 
     
     
         63 . The vector of  claim 62 , wherein the virus comprises a promoter obtained from a mammalian genome. 
     
     
         64 . The vector of  claim 63 , wherein the mammalian genome is a human genome. 
     
     
         65 . The vector of  claim 62 , wherein the virus comprises a promoter obtained from a genome of a virus or a retrovirus. 
     
     
         66 . The vector of  claim 65 , wherein the virus or retrovirus is a polyoma virus, fowlpox virus, adenovirus, bovine papilloma virus, avian sarcoma virus, cytomegalovirus (CMV), hepatitis-B virus, or a Simian Virus 40 (SV40). 
     
     
         67 . A recombinant anti-matrix 2 ectodomain (M2e) antibody comprising a variable heavy chain region encoded by a nucleic acid sequence comprising the nucleic acid sequence of SEQ ID NO: 49 and a variable light chain region encoded by a nucleic acid sequence comprising the nucleic acid sequence of SEQ ID NO: 51. 
     
     
         68 . The antibody of  claim 67 , wherein the nucleic acid sequence comprising the nucleic acid sequence of SEQ ID NO: 49 is a cDNA and the nucleic acid sequence comprising the nucleic acid sequence of SEQ ID NO: 51 is a cDNA. 
     
     
         69 . The antibody of  claim 67 , wherein the nucleic acid sequence of SEQ ID NO: 49 is a cDNA and the nucleic acid sequence of SEQ ID NO: 51 is a cDNA. 
     
     
         70 . A vector comprising a nucleic acid sequence comprising the nucleic acid sequence of SEQ ID NO: 49 and a nucleic acid sequence comprising the nucleic acid sequence of SEQ ID NO: 51. 
     
     
         71 . The vector of  claim 70 , wherein the nucleic acid sequence comprising the nucleic acid sequence of SEQ ID NO: 49 is a cDNA or the nucleic acid sequence comprising the nucleic acid sequence of SEQ ID NO: 51 is a cDNA. 
     
     
         72 . The vector of  claim 70 , wherein the vector is vector suitable for propagation or replication of the nucleic acid. 
     
     
         73 . The vector of  claim 70 , wherein the vector is vector suitable for expressing the nucleic acid. 
     
     
         74 . The vector of  claim 72  or  73 , wherein the vector comprises a virus, a plasmid, or a cosmid. 
     
     
         75 . The vector of  claim 74 , wherein the virus is a recombinant virus. 
     
     
         76 . The vector of  claim 75 , wherein the virus comprises a promoter obtained from a mammalian genome. 
     
     
         77 . The vector of  claim 76 , wherein the mammalian genome is a human genome. 
     
     
         78 . The vector of  claim 75 , wherein the virus comprises a promoter obtained from a genome of a virus or a retrovirus. 
     
     
         79 . The vector of  claim 78 , wherein the virus or retrovirus is a polyoma virus, fowlpox virus, adenovirus, bovine papilloma virus, avian sarcoma virus, cytomegalovirus (CMV), hepatitis-B virus, or a Simian Virus 40 (SV40). 
     
     
         80 . A recombinant anti-matrix 2 ectodomain (M2e) antibody comprising a nucleic acid sequence encoding a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 50 and a nucleic acid sequence encoding a variable light chain region comprising the amino acid sequence of SEQ ID NO: 52. 
     
     
         81 . The antibody of  claim 80 , wherein the nucleic acid sequence encoding a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 50 is a cDNA and the nucleic acid sequence encoding a variable light chain region comprising the amino acid sequence of SEQ ID NO: 52 is a cDNA. 
     
     
         82 . A vector comprising a nucleic acid sequence encoding a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 50 and a nucleic acid sequence encoding a variable light chain region comprising the amino acid sequence of SEQ ID NO: 52. 
     
     
         83 . The vector of  claim 82 , wherein the nucleic acid sequence encoding a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 50 is a cDNA or the nucleic acid sequence encoding a variable light chain region comprising the amino acid sequence of SEQ ID NO: 52 is a cDNA. 
     
     
         84 . The vector of  claim 82 , wherein the vector is vector suitable for propagation or replication of the nucleic acid. 
     
     
         85 . The vector of  claim 82 , wherein the vector is vector suitable for expressing the nucleic acid. 
     
     
         86 . The vector of  claim 84  or  85 , wherein the vector comprises a virus, a plasmid, or a cosmid. 
     
     
         87 . The vector of  claim 86 , wherein the virus is a recombinant virus. 
     
     
         88 . The vector of  claim 87 , wherein the virus comprises a promoter obtained from a mammalian genome. 
     
     
         89 . The vector of  claim 88 , wherein the mammalian genome is a human genome. 
     
     
         90 . The vector of  claim 87 , wherein the virus comprises a promoter obtained from a genome of a virus or a retrovirus. 
     
     
         91 . The vector of  claim 90 , wherein the virus or retrovirus is a polyoma virus, fowlpox virus, adenovirus, bovine papilloma virus, avian sarcoma virus, cytomegalovirus (CMV), hepatitis-B virus, or a Simian Virus 40 (SV40).

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.